Clinical Trials Logo

Primary Peritoneal Cancer clinical trials

View clinical trials related to Primary Peritoneal Cancer.

Filter by:

NCT ID: NCT06173037 Not yet recruiting - Clinical trials for Primary Peritoneal Cancer

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Start date: December 31, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (PROC).

NCT ID: NCT06063070 Not yet recruiting - Ovarian Cancer Clinical Trials

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Start date: October 18, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center Phase II study of fluzoparib combined with bevacizumab for maintenance therapy after first-line platinum-containing chemotherapy in patients with BRCA wild-type advanced ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib plus bevacizumab.

NCT ID: NCT06014190 Recruiting - Ovarian Cancer Clinical Trials

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Start date: December 18, 2023
Phase: Phase 2
Study type: Interventional

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.

NCT ID: NCT05870748 Recruiting - Ovarian Cancer Clinical Trials

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Start date: July 12, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

NCT ID: NCT05739981 Recruiting - Ovarian Cancer Clinical Trials

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

MRD
Start date: February 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

NCT ID: NCT05665023 Recruiting - Clinical trials for Fallopian Tube Cancer

Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Start date: October 28, 2022
Phase: Phase 2
Study type: Interventional

This research study is evaluating a modified FOLFIRINOX plus bevacizumab therapy for mucinous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

NCT ID: NCT05574673 Recruiting - Ovarian Cancer Clinical Trials

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

HERO
Start date: December 1, 2022
Phase:
Study type: Observational

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.

NCT ID: NCT05494580 Recruiting - Ovarian Cancer Clinical Trials

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Start date: September 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor [VEGFR]1, VEGFR 2, VEGFR3 and Fibroblast Growth Factor Receptor 1 [FGFR1]) and immune evasion (via Colony Stimulating Factor 1 Receptor [CSF1R]). In this trial, we aimed to evaluate the efficacy, safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors.

NCT ID: NCT05456685 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

IMGN853 With Carboplatin in Second-line Treatment of FRĪ± Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Start date: September 28, 2022
Phase: Phase 2
Study type: Interventional

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

NCT ID: NCT05329545 Terminated - Clinical trials for Fallopian Tube Cancer

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

UP-NEXT
Start date: June 23, 2022
Phase: Phase 3
Study type: Interventional

UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.